The effect of sulfasalazine in pentylenetetrazole-induced seizures in rats

We aimed to reveal the anti-convulsant effects sulfasalazine and its mechanism in pentylenetetrazole (PTZ)-induced seizures in rats. Forty-eight male Wistar albino rats (200-250 g) were randomly divided into two groups: 24 for electroencephalography (EEG) recording (group A) and 24 for behavioral studies (group B). About 70 mg/kg PTZ was used for behavioral studies after sulfasalazine administration and 35 mg/kg PTZ was used for EEG recording after sulfasalazine administration. Electrodes were implanted on the dura mater over the left frontal cortex and the reference electrode was implanted over the cerebellum for EEG recording. Racine’s convulsion scale, first myoclonic jerk onset time, spike percentages, brain malondialdehyde (MDA), superoxide dismutase (SOD), and prostaglandin F2α (PGF2α) levels were evaluated between the groups. First myoclonic jerk onset time was significantly shorter in the saline group than both 250 and 500 mg/kg sulfasalazine groups (P<0.05). Racine''s convulsion scores were significantly lower in the 250 and 500 mg/kg sulfasalazine groups than the saline group (P<0.05, P<0.001). The two sulfasalazine groups had lower spike percentages than the saline group (P<0.05). Significantly lower MDA and PGF2α levels were observed in the 250 and 500 mg/kg sulfasalazine groups compared with the saline group (P<0.05, P<0.001, respectively). SOD increased significantly in both sulfasalazine groups compared with the PTZ+saline group (P<0.05). Our study demonstrated that sulfasalazine had protective effects on PTZ-induced convulsions by protecting against oxidative and inflammatory damage associated with PTZ.     

柳氮磺胺吡啶对溃疡性结肠炎病理学特征和分级的影响

目的　从病理学角度探讨柳氮磺胺吡啶 (SASP)治疗溃疡性结肠炎 (UC)的部分机制。方法　应用SASP 1g ,每日 3次 ,治疗活动期UC 6周 ,观察治疗前后的病理特征和组织学分级的变化。 结果　轻度UC治疗前黏膜固有层血管炎为 48.2 % ,治疗后为 17.4% (P <0 .0 0 1) ;中度UC治疗前为6 8.0 % ,治疗后为 2 6 .7% (P <0 .0 0 1)。治疗前 ,血管壁轻度坏死 1例 ,中度 2例 ;血栓形成中度 2例 ;在6周末 ,所有标本均未发现有血管壁坏死和血栓形成。治疗前轻度UC腺体异常为 30 .4% ,治疗后为13 .0 % (P <0 .0 5 ) ;治疗前中度UC为 42 .0 % ,治疗后为 40 .0 % (P >0 .0 5 )。轻度UC治疗前嗜酸性粒细胞浸润为 98.2 % ,治疗后为 80 .4% (P <0 .0 1) ;中度UC治疗前为 10 0 .0 % ,治疗后为 91.1% (P <0 .0 5 )。对隐窝脓肿的影响 ,轻度 :从 2 1.4%降到 4.4% (P <0 .0 5 ) ;中度 :从 48.0 %降到 13 .3% (P <0 .0 0 1)。黏膜组织学分级轻度 :治疗前为 2 .0 0± 0 .84,治疗后为 0 .91± 0 .46 (P <0 .0 0 1) ;中度 :治疗前为 2 .49± 0 .84,治疗后为 1.31± 0 .75 (P <0 .0 0 1)。结论　SASP能明显改善UC炎症黏膜的小血管病变与黏膜腺隐窝脓肿 ,减少中性粒细胞和嗜酸性粒细胞的浸润 ,从而减少炎症性反应物产生与前列腺素的合成 ,     

奥沙拉嗪与水杨酸偶氮磺胺吡啶灌肠治疗溃疡性结肠炎的疗效对比观察

目的比较奥沙拉嗪与水杨酸偶氮磺胺吡啶（SASP）用灌肠方法治疗活动期溃疡性结肠炎的疗效和不良反应。方法采用随机双盲双模拟方法观察40例活动期溃疡性结肠炎的疗效和不良反应,疗程为4周。结果治疗4周末奥沙拉嗪组总体疗效显效率为70%,临床症状显效率、体征消失率、内镜完全缓解率和组织学完全缓解率分别为60%,45%,75%及60%;SASP组总体疗效显效率为50%,临床症状显效率、体征消失率、内镜完全缓解率和组织学完全缓解率分别为50%,30%,55%及50%,2组相比有显著性差异（P〈0.05）。结论用奥沙拉嗪灌肠方法治疗活动期溃疡性结肠炎有较好的疗效,且主要不良反应腹泻明显减少。     

奥沙拉秦钠胶囊和柳氮磺胺吡啶片治疗溃疡性结肠炎的随机对照研究

目的评价奥沙拉秦钠胶囊治疗溃疡性结肠炎(UC)的临床疗效与安全性.方法采用随机对照试验,将符合入选标准的UC患者135例,分成治疗组105例,对照组30例.治疗组奥沙拉秦钠胶囊1 g,3次/d,餐中服用;对照组柳氮磺胺吡啶片(SASP)1.0 g,4次/d,餐后服用;疗程均为4周.结果治疗组和对照组的临床疗效分别为86.0%和76.7%.腹泻、腹痛、黏液血便总有效率,在治疗组中分别为85.6%、91.3%、92.5%;对照组中分别为84.0%、90.0%、68.0%.黏液血便改善治疗组较对照组为优(P＜0.05).结肠镜下疗效观察治疗组显著优于对照组(P＜0 01),其有效率分别为79.4%和42.9%.治疗组不良反应以腹泻最常见(20.0%),有5例在治疗初期因腹泻加重而中途退出.其次为恶心、上腹不适、皮疹等.对照组以白细胞减少多见(33.3%),其次为恶心、皮疹、上腹不适等.结论奥沙拉秦钠胶囊治疗UC是一种安全有效的药物.     

双醋瑞因胶囊联合柳氮磺胺吡啶肠溶片与右旋布洛芬胶囊治疗强直性脊柱炎

目的:观察双醋瑞因胶囊联合柳氮磺胺吡啶肠溶片与右旋布洛芬胶囊治疗强直性脊柱炎的临床疗效及安全性。方法:将60例强直性脊柱炎患者随机分为2组,治疗组(40例)采用双醋瑞因胶囊联合柳氮磺胺吡啶肠溶片与右旋布洛芬胶囊治疗,对照组(20例)采用柳氮磺胺吡啶肠溶片与右旋布洛芬胶囊治疗。3个疗程后比较2组患者血沉下降幅度、C反应蛋白下降幅度、关节痛和腰背部疼痛评分变化情况及总体疗效。结果:①治疗组血沉下降幅度大于对照组(t=2.509,P=0.017);治疗组与对照组C反应蛋白下降幅度比较,差异无统计学意义(t=-0.078,P=0.938);治疗组关节痛和腰背部疼痛评分下降幅度大于对照组(t=-2.686,P=0.010)。②治疗组临床疗效优于对照组(Z=-2.106,P=0.035)。③治疗组不良反应主要表现为轻度腹泻3例,上腹部疼痛2例,白细胞数升高2例,白细胞数降低1例,恶心、呕吐1例;对照组不良反应主要表现为腹胀2例,恶心1例,肝功能轻度异常1例。2组患者均未出现尿常规及肾功能明显异常。结论:采用双醋瑞因胶囊联合柳氮磺胺吡啶肠溶片与右旋布洛芬胶囊治疗AS,能够降低急性期反应物指标,缓解关节及腰背部疼痛,疗效确切,且不良反应轻微,值得临床推广引用。     

The usefulness of a new triple combination treatment utilizing methotrexate,salazosulfapyridine, and bucillamine in rheumatoid arthritis

Objectives. Combination treatment with methotrexate, salazosulfapyridine and bucillamine as an alternative to treatment with TNF-inhibiting biologics in rheumatoid arthritis was investigated.

Methods. Twenty-six facilities allied with the Japan Association of Rheumatologists in Private Practice participated in this study. One hundred and twelve patients enrolled in this study, all of whom were within 3 years of diagnosis with rheumatoid arthritis for whom treatment with one DMARD or a combination of two DMARDs had failed (DAS28 > 3.2). Patients chose their own treatment. The triple DMARDs combination group was comprised of 72 patients; the TNF-inhibiting biologics treatment group was comprised of 40 patients.

Results. DAS28 scores for the triple DMARDs combination group and the TNF-inhibiting biologics treatment groups were 4.84 ± 0.96 and 5.23 ± 1.26, and there was no significant difference between the two groups. From the 6th month, average disease activities of both groups were reduced, and there was no difference between the two groups at 12 months (DAS28, 3.39 ± 1.43 and 3.05 ± 1.43, p = 0.39). Furthermore, there was no significant difference in the degree of bone destruction between the two groups at 12 months.

Conclusions. The triple DMARD combination therapy provided a new treatment option for those patients for whom treatment with biologics is difficult.     

资生丸联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎的临床研究

目的探讨资生丸联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎的临床疗效。方法选择2018年3月—2020年3月河南医学高等专科学校附属医院收治的113例溃疡性结肠炎患者,根据随机分层抽样法分为对照组(56例)和治疗组(57例)。对照组口服柳氮磺吡啶肠溶片,1 g/次,3次/d。治疗组在对照组治疗的基础上口服资生丸,10丸/次,3次/d。两组均治疗4周。观察两组临床疗效,比较两组临床症状改善时间、疾病活动指数(DAI)评分、血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平。结果治疗后,治疗组的总有效率91.23%,比对照组的73.21%更高(P<0.05)。治疗后,治疗组治愈时间、黏液脓血便消失时间、黏膜愈合时间短于对照组(P<0.05)。治疗后,两组患者DAI评分均下降(P<0.05),且治疗组DAI评分低于对照组(P<0.05)。治疗后,两组TNF-α、IL-8、CRP水平均显著下降(P<0.05),且治疗组TNF-α、IL-8、CRP水平较对照组更低(P<0.05)。结论资生丸联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎患者可改善临床症状,同时还可降低血清IL-8、TNF-α、CRP水平,具有较好的疗效。     

中西医结合治疗溃疡性结肠炎临床观察

目的观察柳氮磺胺吡啶联合肠胃康片治疗溃疡性结肠炎的临床疗效。方法 90例溃疡性结肠炎患者随机分为两组,对照组给予柳氮磺胺吡啶口服,治疗组给予柳氮磺胺吡啶联合肠胃康片口服,治疗1个月后比较两组疗效。结果治疗组总有效率明显优于对照组(P0.01)。结论柳氮磺胺吡啶联合肠胃康治疗溃疡性结肠炎效果明显好于单纯使用柳氮磺胺吡啶。     

柳氮磺胺吡啶联合微生态制剂治疗溃疡性结肠炎的临床研究

目的：探讨柳氮磺胺吡啶（SASP）联合常美安等微生态制剂治疗溃疡性结肠炎的疗效优势。方法：选择经内镜确诊为溃疡性结肠炎（UC）的患者84例,随机分为对照组（n=42例,单用SASP口服治疗,剂量为1．0g,每日4次）和实验组（n=42例,在口服SASP治疗基础上联用微生态制剂常美安,2粒／次,3次／d）,治疗14周后,比较两组Sutherland疾病活动性指数变化情况;采用免疫组化法检测其肠粘膜局部白介素-10（IL-10）,白介素-6（IL-6）、白介素-18（IL-18）等细胞因子的变化;主观评价临床疗效、镜下以及组织学病变改善情况。结果：两组治疗前Sutherland指数比较,差异无统计学意义（P〉0．05）;但经14周治疗后,实验组的Sutherland指数低于对照组,IL-10水平升高以及IL-6、IL-18水平降低幅度均优于对照组,差异具有统计学意义（P〈0．05）;两组在主观评价临床疗效、镜下以及组织学等3方面的病变改善情况比较,差异具有统计学意义（P〈0．05）。结论：SASP联合微生态制剂治疗UC的临床效果明显优于单用SASP,且其不良反应少,安全性高,值得临床推广。     

独活寄生汤联合西药治疗强直性脊柱炎的临床研究

目的探讨独活寄生汤联合甲氨蝶呤、柳氮磺吡啶治疗强直性脊柱炎的临床疗效。方法选取2012年1月—2015年4月在我院风湿科住院治疗的87例强直性脊柱炎患者,随机分成对照组和治疗组。对照组予甲氨蝶呤片联合柳氮磺吡啶片治疗,治疗组在口服上述西药基础上加用独活寄生汤加减治疗,用药3个月后对两组的治疗效果进行评价。结果治疗3个月后,治疗组总有效率达85.71%。与对照组相比,能明显的改善AS患者中医证候积分、BASDAI、BASFI、脊柱痛、指地距等生活功能状态(P0.05),同时对实验室指标hs-CRP、ESR的表达亦有一定的改善作用,且不良事件的发生概率较低。结论独活寄生汤联合甲氨蝶呤、柳氮磺吡啶治疗强直性脊柱炎疗效确切。